Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medivolve Inc MEDVF

Medivolve Inc. is a Canadian healthcare technology company. The Company and its subsidiaries, Medivolve Pharmacy Inc. (doing business as Marbella Pharmacy) and Kedy Ying Jao D.O., a Medical Corporation, operate a distributed network of two retail patient-care locations in California, United States. It has two business units: Medivolve Pharmacy Division (MPD) and Medivolve Clinic Services Division (MCSD). MPD provides retail pharmacy and mail-order pharmacy services related to COVID-19, antibiotics, dermatology, family medicine, immunology, neurology, pain management, pediatrics, preventive medicine and psychiatry to patients in Southern California. MCSD provides licensed healthcare through a clinic in Brea, California, United States. MCSD is focused on developing a telehealth platform, which connects patients with physicians, and facilitates and manages the provision of virtual consultation, diagnosis, and treatment services in partnership with qualified health practitioners.


OTCPK:MEDVF - Post by User

Post by Hiddensecretson Mar 08, 2021 2:46pm
245 Views
Post# 32744802

MEDV needs to pivot towards TELE DIAGNOSTIC services

MEDV needs to pivot towards TELE DIAGNOSTIC services.
Having a mobile clinic is a disruptive medical service.   They have doctors on the road in France and it works very well as a certain amount of the population does not like to go to hospital and they want fast service. 

We need to get away from covid19 testing and, move quickly towards Tele Diagnostic which is a more lucrative and recurring business model.   Investors will pay more for the eps. 

They need to launch the new Nutrcell product into Amazon and large retail stores ASAP.  This can be a billion $$$  business. 

And they need to update us on the cube situation.   Is the covid19 cube business still lucrative or not?  We have no update on February 2021 figures. 

Finally MEDV needs to STOP overpromising things, like 2,000 cubes in 2021 and be realistic with what they can achieve.   No one believes that number so why bother to say it. 

Still long but management did a pretty good job of messing things up with Tim Shelburn, Karland, confusion on cubes (open themselves or franchsie), buying into telehealth or not, dilute shares or not, financing on the cheap or not, etc...

They need to get their act in order.

Maybe a new CEO may have a different outlook. 

MPO



<< Previous
Bullboard Posts
Next >>